Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • STATUS
    Recruiting
  • End date
    Nov 15, 2025
  • participants needed
    30
  • sponsor
    Weill Medical College of Cornell University
Updated on 2 April 2021

Summary

The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).

The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC.

Description

This is a single-arm, open-label Phase II multi-institutional trial in 30 patients that have been molecularly selected based on that their tumors possess alterations in molecular targets of cabozantinib. Patients will be treated be continuously until they develop radiographic progression or discontinue cabozantinib for toxicity. If 6 or more out of 12 subjects with particular mutation or gene amplification show progression prior to 6 months, accrual for the particular genomic alteration may close. In addition, a series of correlative studies will be performed including tissue biopsies in order to further define the mechanisms of cabozantinib anti-tumor action in prostate cancer and identify surrogate markers of response.

This research study is being done because additional effective treatments are needed for prostate cancer that has spread and is growing despite hormone suppression. Prior studies indicate that Cabozantinib may be effective in a subset of these participants, but that has not yet been determined.

About 30 subjects will take part in this study at 4 participating sites. We expect to enroll approximately 20 participants at Weill Cornell Medicine and approximately 3-5 subjects per participating site. All subjects participating in this study will be treated with Cabozantinib. All subjects will continue to take LHRH analogue therapy.

Once eligible participants will be enrolled on the trial for approximately approximately 12 months. At that point, subjects will switch to long-term follow up for two years after removal from the study or until death, whichever occurs first.

Study related procedures can be combined with routine Standard of Care (SOC) visits. These will include obtaining medical history, vitals, routine blood collection, radiographic imaging (CT, MRI and Bone scan), EKG and between 2 and 4 weeks after starting therapy, a tumor biopsy is required. This will be done with a needle by local sedation by an Interventional Radiologist.

Details
Condition Malignant neoplasm of prostate, Prostatic disorder, Prostate Disorders, Prostate Cancer, Early, Recurrent, Prostate Cancer, prostate carcinoma, prostate cancers
Treatment Cabozantinib
Clinical Study IdentifierNCT04631744
SponsorWeill Medical College of Cornell University
Last Modified on2 April 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 99 yrs?
Are you male?
Do you have any of these conditions: prostate carcinoma or prostate cancers or Prostate Cancer, Early, Recurrent or Prostatic disorder or Prostate Cancer or Prostate Disorders or Malignan...?
Do you have any of these conditions: prostate carcinoma or Prostate Cancer or Prostate Disorders or Prostatic disorder or prostate cancers or Prostate Cancer, Early, Recurrent or Malignan...?
Age >18 years
Documented histological or cytological diagnosis of prostate carcinoma
Evidence of metastatic PC on imaging (bone scan and/or CT/MRI scan)
Agree to undergo a biopsy of at least one metastatic site or primary prostate prior to beginning therapy. Adequate archival metastatic tissue can be used if available in lieu of a biopsy if done when patient had CRPC and within 3 months the start of treatment
Agree to undergo a biopsy of at least one metastatic site or primary prostate after 3 weeks weeks of therapy (biopsy must be between day 21 and day 24 of treatment). Rebiopsy of same pre-treatment biopsy soft tissue site is preferred
Serum testosterone level less than 50 ng/dl. Subjects without prior orchiectomy must be currently taking and willing to continue luteinizing hormone-releasing hormone (LHRH) analogue (agonist or antagonist) therapy until permanent discontinuation of study treatment
Previously received either abiraterone acetate and/or enzalutamide or similar AR pathway inhibitor
Previous docetaxel chemotherapy is allowed in hormone-sensitive setting and in castration-resistant disease if not within 12 months of enrolling
Documented progressive metastatic CRPC based on at least one of the following
criteria
PSA progression according to Prostate Cancer Working Group 3 (PCWG3) criteria
Objective radiographic progression, according to PCWG3 criteria
ECOG performance status of 0-1
Recovery to baseline or Grade 1 CTCAE v4 from toxicities related to any prior treatments, unless specified below or AE(s) are clinically nonsignificant and/or stable on supportive therapy
Adequate organ and marrow function, based upon meeting all of the following laboratory criteria within 14 days before first dose of study treatment
Absolute neutrophil count (ANC) 1500/mm3 ( 1.5 GI/L) without granulocyte colony-stimulating factor support
White blood cell count 2500/mm3 ( 2.5 GI/L)
Platelets 100,000/mm3 ( 100 GI/L) without transfusion
Hemoglobin 9 g/dL ( 90 g/L)
Total bilirubin 1.5 x ULN (for subjects with Gilbert's disease 3 x ULN)
Serum albumin 2.8 g/dl
Serum creatinine 2.0 x ULN or calculated creatinine clearance 30 mL/min ( 0.5 mL/sec) using the Cockcroft-Gault equation
If urine dipstick is positive, then: Urine protein/creatinine ratio (UPCR) 1 mg/mg ( 113.2 mg/mmol)
Evidence of amplification or activating mutation of selected targets of cabozantinib (including MET, KIT, RET, VEGFR-1, VEGFR-2, VEGFR-3, FLT3, AXL, TRKB, or TIE2) by at least one of the following
DNA sequencing of metastatic tumor biopsy specimen or cfDNA test
RNA sequencing of metastatic tumor biopsy specimen
Commercial cell-free DNA assay
Overexpression by IHC on metastatic tumor biopsy specimen
Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment
Capable of understanding and complying with the protocol requirements and must have signed the informed consent document

Exclusion Criteria

Prior treatment with cabozantinib
Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment
Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) except agents to maintain castrate status within 4 weeks before first dose of study treatment. Antiresportive bone agents are also allowed
Subject has received abiraterone acetate or enzalutamide within 2 weeks before enrollment
Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to first dose of study treatment after radiotherapy or at least 4 weeks prior to first dose of study treatment after major surgery (e.g., removal or biopsy of brain metastasis). Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment for neurological indications at the time of first dose of study treatment
Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following
Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH)
Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor
The subject has prothrombin time (PT)/INR or partial thromboplastin time (PTT) test 1.3 x the laboratory ULN within 7 days before the first dose of study treatment
The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions
Cardiovascular disorders
Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias
Uncontrolled hypertension defined as sustained blood pressure (BP) >140 mm Hg systolic or >90 mm Hg diastolic despite optimal antihypertensive treatment
Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g. deep venous thrombosis, pulmonary embolism) within 6 months before first dose
Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation
The subject has evidence of tumor invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction
Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose
Note: Complete healing of an intra-abdominal abscess must be confirmed before
first dose
Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 mL) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose
Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation
Lesions invading or encasing any major blood vessels. Subjects with lesions invading the intrahepatic vasculature, including portal vein, hepatic vein, and hepatic artery, are eligible
Other clinically significant disorders that would preclude safe study participation
Serious non-healing wound/ulcer/bone fracture
Uncompensated/symptomatic hypothyroidism
Moderate to severe hepatic impairment (Child-Pugh B or C). 10. Major surgery (e.g., GI surgery, removal or biopsy of brain metastasis) within 8 weeks before first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before first dose and from minor surgery (e.g. simple excision, tooth extraction) at least 10 days before first dose. Subjects with clinically relevant ongoing complications from prior surgery are not eligible. 11. Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment [add reference for Fridericia formula]
Note: If a single ECG shows a QTcF with an absolute value > 500 ms, two
additional ECGs at intervals of approximately 3 min must be performed within
min after the initial ECG, and the average of these three consecutive
results for QTcF will be used to determine eligibility
\. Inability to swallow tablets
\. Previously identified allergy or hypersensitivity to components of the
study treatment formulations
\. Diagnosis of another malignancy within 2 years before first dose of study
treatment, except for superficial skin cancers, or localized, low-grade tumors
deemed cured and not treated with systemic therapy
Molecular Eligibility
To be eligible, a patient's tumor must have evidence of gene amplification, an
activating mutation, or overexpression of one of the following genes: MET
KIT, RET, VEGFR-1, VEGFR-2, VEGFR-3, FLT3, AXL, TRKB, or TIE2. Eligibility can
be met via the following diagnostic
tests
DNA sequencing of a metastatic tumor biopsy specimen showing gene amplification or activating mutation using a CLIA-certified assay. Tumor tissue samples must have been collected within 6 months of enrollment
Protein overexpression in a metastatic tumor biopsy specimen determined by immunohistochemistry (IHC) showing 2+ or 3+ protein expression using a CLIA-certified assay.These include common in-house KIT and commercial reference labs for panTRK (e.g. NeoGenomics) and cMET (e.g. NeoGenomics, Caris, Mayo Clinic)
CLIA-certified commercial cell free DNA assay reporting gene amplification or activating mutation within 3 months of enrollment
For the Guardant360 Liquid Biopsy amplification must be at least (++) or (+++) for to meet eligibility
For the FoundationOneLiquid assay, amplification will be eligible. Reports that have an "equivocal" or "subclonal" designation will not be eligible
Any non-CLIA certified assay such as RNA expression profiling of a metastatic tumor biopsy specimen showing overexpression must be confirmed by a CLIA-certified assay (i.e., immunohistochemistry showing 2+ or 3+ protein expression)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note